Literature DB >> 7718615

Purification and partial amino acid sequencing of a fructosyllysine-specific binding protein from cell membranes of the monocyte-like cell line U937.

S Krantz1, R Salazar, R Brandt, J Kellermann, F Lottspeich.   

Abstract

The ability of short-term in vitro glycated albumin to react with monocytes or the monocyte-like cells U937 is due to the Amadori adduct fructosyllysine. Two binding proteins of about 100 and 200 kDa have been previously described to interact specifically with the monocyte-like cell line U937. Detergent extracts from U937 cell membranes were used to purify the 100kDa protein by ion exchange chromatography, fructosyllysine-Sepharose affinity chromatography and SDS-PAGE. Six amino acids from the N-terminal end and two peptide sequences of 14 and 15 amino acids were identical with the N-terminus and the positions 349 to 362 and 610 to 624 of the major nuclear protein nucleolin. However, ligand blotting experiments with nuclear extracts from U937 and RIN cells showed no binding of glycated albumin with nucleolin. The reported amino acid sequences of the 100kDa fructosyllysine specific binding protein do not show any homologies with AGE-receptors. This receptor protein as a nucleolin-like polypeptide belongs to the superfamily of RNA-binding proteins.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7718615     DOI: 10.1016/0167-4889(95)00028-q

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

Review 1.  [Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus].

Authors:  P P Nawroth; A Bierhaus; G E Vogel; M A Hofmann; M Zumbach; P Wahl; R Ziegler
Journal:  Med Klin (Munich)       Date:  1999-01-15

2.  Identification of nucleolin as a new L-selectin ligand.

Authors:  G Harms; R Kraft; G Grelle; B Volz; J Dernedde; R Tauber
Journal:  Biochem J       Date:  2001-12-15       Impact factor: 3.857

3.  Purification and characterization of a 200 kDa fructosyllysine-specific binding protein from cell membranes of U937 cells.

Authors:  R Salazar; R Brandt; J Kellermann; S Krantz
Journal:  Glycoconj J       Date:  2000-10       Impact factor: 2.916

Review 4.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.

Authors:  Paula J Bates; Damian A Laber; Donald M Miller; Shelia D Thomas; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-20       Impact factor: 3.362

5.  Differential expression of fructosyllysine-specific receptors on monocytes and macrophages and possible pathophysiological significance.

Authors:  R Brandt; C Landmesser; L Vogt; B Hehmke; R Hanschke; J Kasbohm; K Hartmann; B Jäger; S Krantz; D Michaelis
Journal:  Diabetologia       Date:  1996-10       Impact factor: 10.122

6.  Characterization of a 100-kilodalton binding protein for the six serotypes of coxsackie B viruses.

Authors:  U R de Verdugo; H C Selinka; M Huber; B Kramer; J Kellermann; P H Hofschneider; R Kandolf
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Ecto-protein kinase substrate p120 revealed as the cell-surface-expressed nucleolar phosphoprotein Nopp140: a candidate protein for extracellular Ca2+-sensing.

Authors:  D Kübler
Journal:  Biochem J       Date:  2001-12-15       Impact factor: 3.857

8.  Role of nucleolin in human parainfluenza virus type 3 infection of human lung epithelial cells.

Authors:  Santanu Bose; Mausumi Basu; Amiya K Banerjee
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

9.  Binding of Amadori glucose-modified albumin by the monocytic cell line MonoMac 6 activates protein kinase C epsilon protein tyrosine kinases and the transcription factors AP-1 and NF-kappaB.

Authors:  R Salazar; R Brandt; S Krantz
Journal:  Glycoconj J       Date:  2001-10       Impact factor: 2.916

Review 10.  Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications.

Authors:  Margo P Cohen; Fuad N Ziyadeh; Sheldon Chen
Journal:  J Lab Clin Med       Date:  2006-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.